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Background
Chronic hepatitis C (HCV) infects approximately 170 mil-
lion people and causes more than 350 000 deaths every
year. Information regarding pathogenetic mechanism of
acute hepatitis C infection is limited. Following innate
immune activation, cellular immunity, including natural
killer (NK) cell activation and antigen-specific CD8 cell
proliferation occurs. CD8+ T lymphocytes directly kill
infected cells via direct cell-cell contact, and release anti-
viral cytokines (e.g. IFN, TNF)
Methods
Eleven HCV-treatment naive HCV infected patients
were treated with weight-based ribavirin daily in addi-
tion to either weekly pegIFN alfa-2b at 1.5 ug/kg, weekly
pegIFN alfa-2a, or albinterferon alfa-2b at 900mcg every
2 weeks. All patients gave written informed consent
approved by the Institutional Review Board prior to
enrollment in the studies. Intensive serum monitoring
was completed at study visits day 0 (pretreatment),
weeks 4, 6 and 12.
Results
In this present study, we aimed to investigate the rela-
tionship between IFN treatment response, HCV viral
load and sApo 2L levels. Eleven HCV-treatment naive
HCV infected patients were treated with pegIFN alfa-2a.
Intensive serum circulating Apo 2L levels were moni-
tered at study visits day 0 (pretreatment), weeks 4, 6
and 12.HCV-RNA and sApo 2L levels decreased gradu-
ally with PegIF-a 2 treatment and the differences were
significant between day 0 and 4th week (p=0.001,
p<0.005 and p=0.01, p<0.005 respectively); between day
0 and 12th week (p=0.001, p<0.005 and p=0.001,
p<0.000 respectively); between 6th week and 12th week
(p=0.01, p<0.05 and p=0.01, p<0.05 respectively).
Conclusions
We suggest that, decreased level of circulating Apo 2L
may reflect its increased binding to its ligand expressed
on hepatocyte or lymphocyte under the influence of
PegIFN treatment.
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